Compare Stocks: NBIX, MRNA, QGEN, TECH, and ARGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$998.10 +1.4%	$934.10	$661.85 ▼ $1,072.75	$62.56B	0.47	337,587 shs	597 shs
MRNA Moderna	$143.37 -0.4%	$92.35	$22.28 ▼ $176.66	$57.42B	1.1	11.56 million shs	192,968 shs
NBIX Neurocrine Biosciences	$157.56 +0.9%	$164.46	$122.14 ▼ $186.12	$16.12B	0.38	1.19 million shs	703 shs
QGEN Qiagen	$42.70 +0.5%	$42.20	$32.53 ▼ $57.81	$8.84B	0.63	2.49 million shs	728 shs
TECH Bio-Techne	$72.21 +0.1%	$71.98	$43.19 ▼ $72.62	$11.32B	1.28	3.33 million shs	1,575 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-4.72%	+15.64%	+11.33%	+30.14%
MRNA Moderna	0.00%	-1.09%	+127.37%	+176.17%	+512.38%
NBIX Neurocrine Biosciences	0.00%	+0.37%	+2.29%	-2.06%	+10.11%
QGEN Qiagen	0.00%	-2.23%	-1.27%	+14.68%	-11.10%
TECH Bio-Techne	0.00%	-0.43%	-0.39%	+28.40%	+40.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$998.10 +1.4%	$934.10	$661.85 ▼ $1,072.75	$62.56B	0.47	337,587 shs	597 shs
MRNA Moderna	$143.37 -0.4%	$92.35	$22.28 ▼ $176.66	$57.42B	1.1	11.56 million shs	192,968 shs
NBIX Neurocrine Biosciences	$157.56 +0.9%	$164.46	$122.14 ▼ $186.12	$16.12B	0.38	1.19 million shs	703 shs
QGEN Qiagen	$42.70 +0.5%	$42.20	$32.53 ▼ $57.81	$8.84B	0.63	2.49 million shs	728 shs
TECH Bio-Techne	$72.21 +0.1%	$71.98	$43.19 ▼ $72.62	$11.32B	1.28	3.33 million shs	1,575 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-4.72%	+15.64%	+11.33%	+30.14%
MRNA Moderna	0.00%	-1.09%	+127.37%	+176.17%	+512.38%
NBIX Neurocrine Biosciences	0.00%	+0.37%	+2.29%	-2.06%	+10.11%
QGEN Qiagen	0.00%	-2.23%	-1.27%	+14.68%	-11.10%
TECH Bio-Techne	0.00%	-0.43%	-0.39%	+28.40%	+40.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.88	Moderate Buy	$1,158.61	17.70% Upside
MRNA Moderna	2.08	Hold	$76.72	-46.71% Downside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.09	28.72% Upside
QGEN Qiagen	2.43	Hold	$43.51	2.64% Upside
TECH Bio-Techne	2.12	Hold	$68.92	-4.43% Downside

Current Analyst Ratings Breakdown

Latest QGEN, NBIX, MRNA, TECH, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	QGEN Qiagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/11/2026	QGEN Qiagen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$182.00 ➝ $183.00
9/9/2026	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	QGEN Qiagen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$52.00 ➝ $47.00
9/9/2026	QGEN Qiagen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/8/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
9/8/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$198.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
9/3/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,150.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	14.50	$21.33 per share	46.15	$118.34 per share	8.32
MRNA Moderna	$1.94B	29.57	N/A	N/A	$22.14 per share	6.50
NBIX Neurocrine Biosciences	$2.86B	5.55	$5.01 per share	31.17	$32.63 per share	4.79
QGEN Qiagen	$2.09B	4.18	$3.40 per share	12.48	$17.89 per share	2.37
TECH Bio-Techne	$1.22B	9.31	$2.35 per share	30.72	$13.47 per share	5.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	37.80	26.41	1.02	32.19%	43.59%	36.66%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	22.91	16.51	0.73	20.91%	22.43%	15.64%	10/27/2026 (Estimated)
QGEN Qiagen	$424.88M	$1.95	21.72	15.64	4.23	19.49%	14.47%	8.34%	11/3/2026 (Estimated)
TECH Bio-Techne	$181.86M	$1.15	62.71	36.24	8.58	14.97%	13.23%	10.61%	11/4/2026 (Estimated)

Latest QGEN, NBIX, MRNA, TECH, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q4 2026	TECH Bio-Techne	$0.5190	$0.52	+$0.0010	$0.35	$314.63 million	$321.19 million
8/5/2026	Q2 2026	QGEN Qiagen	$0.5980	$0.62	+$0.0220	$0.50	$527.50 million	$535.04 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	$0.35	0.83%	N/A	17.95%	N/A
TECH Bio-Techne	$0.32	0.44%	N/A	27.83%	N/A

Latest QGEN, NBIX, MRNA, TECH, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/12/2026	TECH Bio-Techne	quarterly	$0.65	0.44%	8/24/2026	8/24/2026	9/4/2026
8/12/2026	TECH Bio-Techne	quarterly	$0.08	0.44%	8/17/2026	8/17/2026	8/28/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
MRNA Moderna	0.09	2.29	2.18
NBIX Neurocrine Biosciences	N/A	1.87	1.75
QGEN Qiagen	0.48	2.85	2.31
TECH Bio-Techne	0.09	4.55	3.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
MRNA Moderna	75.33%
NBIX Neurocrine Biosciences	92.59%
QGEN Qiagen	70.00%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
MRNA Moderna	10.80%
NBIX Neurocrine Biosciences	4.60%
QGEN Qiagen	9.00%
TECH Bio-Techne	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
QGEN Qiagen	5,654	206.07 million	187.53 million	Optionable
TECH Bio-Techne	3,000	156.82 million	154.78 million	Optionable

NBIX, MRNA, QGEN, TECH, and ARGX Headlines

Recent News About These Companies

HB Wealth Management LLC Sells 24,595 Shares of Bio-Techne Corp $TECH

September 14 at 3:51 AM | marketbeat.com

California State Teachers Retirement System Boosts Stock Position in Bio-Techne Corp $TECH

September 14 at 3:11 AM | marketbeat.com

Wellington Management Group LLP Sells 5,109,880 Shares of Bio-Techne Corp $TECH

September 13 at 4:31 AM | marketbeat.com

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

September 11 at 12:31 PM | zacks.com

WINTON GROUP Ltd Takes $4.75 Million Position in Bio-Techne Corp $TECH

September 11 at 5:12 AM | marketbeat.com

Bio-Techne Corp $TECH Shares Acquired by Squarepoint Ops LLC

September 11 at 5:04 AM | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Given Average Rating of "Hold" by Analysts

September 11 at 4:28 AM | marketbeat.com

Amundi Has $129.09 Million Position in Bio-Techne Corp $TECH

September 10, 2026 | marketbeat.com

Bio Techne

September 9, 2026 | moneycontrol.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

September 9, 2026 | globenewswire.com

Maven Securities LTD Purchases Shares of 54,711 Bio-Techne Corp $TECH

September 9, 2026 | marketbeat.com

Hsbc Holdings PLC Has $17.11 Million Stock Position in Bio-Techne Corp $TECH

September 9, 2026 | marketbeat.com

Carmignac Gestion Purchases New Holdings in Bio-Techne Corp $TECH

September 8, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Makes New Investment in Bio-Techne Corp $TECH

September 5, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $38.22 Million Stock Position in Bio-Techne Corp $TECH

September 4, 2026 | marketbeat.com

Alyeska Investment Group L.P. Sells 655,358 Shares of Bio-Techne Corp $TECH

September 2, 2026 | marketbeat.com

Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

September 1, 2026 | prnewswire.com

Jupiter Topco LLC Makes New $4.82 Million Investment in Bio-Techne Corp $TECH

September 1, 2026 | marketbeat.com

Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks

August 31, 2026 | finance.yahoo.com

Moore Capital Management LP Acquires Shares of 125,626 Bio-Techne Corp $TECH

August 31, 2026 | marketbeat.com

Van ECK Associates Corp Cuts Position in Bio-Techne Corp $TECH

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NBIX, MRNA, QGEN, TECH, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$998.10 +13.71 (+1.39%)

As of 09:38 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Moderna NASDAQ:MRNA

$143.14 -0.83 (-0.58%)

As of 09:38 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Neurocrine Biosciences NASDAQ:NBIX

$157.56 +1.34 (+0.86%)

As of 09:38 AM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Qiagen NYSE:QGEN

$42.70 +0.19 (+0.46%)

As of 09:38 AM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Bio-Techne NASDAQ:TECH

$72.21 +0.09 (+0.12%)

As of 09:38 AM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QGEN, NBIX, MRNA, TECH, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QGEN, NBIX, MRNA, TECH, and ARGX Earnings

Compare Dividends

Latest QGEN, NBIX, MRNA, TECH, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBIX, MRNA, QGEN, TECH, and ARGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NBIX, MRNA, QGEN, TECH, and ARGX Company Descriptions

argenex NASDAQ:ARGX

Moderna NASDAQ:MRNA

Neurocrine Biosciences NASDAQ:NBIX

Qiagen NYSE:QGEN

Bio-Techne NASDAQ:TECH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools